New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
Dupixent peak sales ambition raised to more than €13 billion
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
As a partner with IRIA, the company had a significant booth presence on-ground during the conference.
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Subscribe To Our Newsletter & Stay Updated
